The study ‘Benefits of a Clinical Research Strategy for Turkey’ (2020), conducted by IQVIA and commissioned by AIFD and EFPIA, looked at the potential benefits for Turkey of a strategy to facilitate and attract further investments in clinical research. It also included recommendations on how to implement such a strategy successfully.
Sule Sencer Akbil, Engagement Manager, Consulting & Services, IQVIA
Dr Koen Berden, Executive Director International Affairs, EFPIA
Dr César Hernandez García, Head of Department, Department of Medicines for Human Use, (AEMPS, Spanish Medicines Agency)
Nathalie Lambot, Expert Public Health – Clinical Trials & Regulatory Affairs, pharma.be
Assoc. Prof. Tolga Tolunay, Deputy Minister of Health, Turkey (TBC)
If you have any questions or require additional information, please contact our Communications Team at firstname.lastname@example.org